In 2017, Qing Wang pioneered the first clinical proteomics platform for cancer diagnostics, demonstrating that deep measurement of the human plasma proteome could power a new generation of scalable molecular diagnostics.
First Clinical Proteomics Platform for Early Ovarian Cancer Detection
In 2017, Qing Wang and collaborators reported one of the earliest demonstrations that clinical proteomics could be used to build a molecular diagnostic platform for early cancer detection. The work represented a major step in translating targeted proteomics technologies from academic research into practical clinical applications.
During the preceding decade, cancer genomics had revealed the genetic architecture of many tumors. Yet early detection remained one of the greatest challenges in oncology. Most cancers are diagnosed only after symptoms appear, when treatment options are far less effective. While genomic sequencing had transformed research, it was not yet optimized for routine detection of early-stage disease in blood samples.
Wang and his collaborators believed that proteins circulating in blood could provide a powerful molecular signal for early detection if measured with sufficient sensitivity and reproducibility.
Building a Clinical Proteomics Diagnostic Strategy
To address this challenge, Wang’s team developed a highly sensitive targeted proteomics workflow capable of detecting extremely low-abundance proteins in plasma. By combining optimized sample preparation, high-resolution mass spectrometry, and quantitative peptide assays, the platform enabled systematic measurement of candidate biomarkers associated with ovarian cancer.
Using this strategy, the researchers demonstrated that protein biomarkers could be detected and quantified in patient plasma samples with high specificity, opening the possibility of developing blood-based molecular tests for early cancer detection.
This work represented one of the earliest practical demonstrations that clinical proteomics could move beyond discovery research and support the development of deployable diagnostic assays.
A New Direction for Translational Proteomics
The success of this study reinforced a key insight that had guided Wang’s research since his early training in the laboratory of Bert Vogelstein at Johns Hopkins University School of Medicine:
Genomics can identify disease-associated mutations, but proteomics provides a direct measurement layer for monitoring disease biology in real patient samples.
This realization helped shape a broader scientific vision—to develop scalable technologies capable of measuring thousands of proteins from clinical specimens such as blood, tissue, and other biological fluids.
The Foundation for Complete360®
The ovarian cancer study also served as an important technological foundation for future platform development. The lessons learned from building high-sensitivity targeted assays for plasma proteins ultimately informed the design of more comprehensive systems capable of measuring the human proteome at unprecedented depth.
These efforts eventually evolved into the Complete360® platform, which enables ultra-deep measurement of thousands of proteins across large clinical cohorts and supports applications ranging from early disease detection to precision therapeutics.
What began as a targeted clinical proteomics experiment in ovarian cancer would later grow into a broader mission: building the measurement infrastructure necessary to transform proteomics into a scalable clinical technology for precision medicine.
At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, consetetur sadipscing elitr.